


CLAIMS

1. A compound of the following Formula I:



5

I

wherein

A is hydrogen or hydroxy;

B is selected from optionally substituted carbocyclic aryl and optionally substituted heteroalicyclic having from 3 to 8 ring atoms and at least 1 N, O or S ring atom or a heteroaromatic group having a single ring with 5 or 6 ring atoms and at least one N, O or S ring atom;

U is $(CH_2)_p$ wherein p is selected from 0, 1 and 2;

V and Q are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, C₁-C₆ heteroalkyl, C₃-C₆ cycloalkyl C₁-C₆ alkyl, C₃-C₆ heterocycloalkyl C₁-C₆ alkyl, arylalkyl, -CR¹R²-W, wherein R¹ and R² are independently selected from H and C₁-C₆ alkyl; or R¹ and R² can form an C₃-C₆ cycloalkyl with the carbon they are attached to;

W is selected from hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl C₁-C₆ alkyl, aryl and heteroaryl; with at least one of V and Q being other than hydrogen; and pharmaceutically acceptable salts thereof.


2. A compound of claim 1 wherein A is hydrogen.

25 3. A compound of any one of claims 1 or 2 wherein B is optionally substituted carbocyclic aryl.

4. A compound of any one of claims 1 through 3 wherein B is optionally substituted phenyl.

30

5. A compound of claim 1 having the following Formula II:



5 wherein R is C(=O)Z where Z is selected from hydrogen, hydroxy, optionally substituted alkoxy and optionally substituted alkyl; or R is amino or optionally substituted alkylamine;

X is selected from oxygen, sulfur, sulfinyl, sulfonyl and carbon;


n is an integer selected from 0, 1, 2, 3, 4 and 5;

10 U is (CH₂)_p, wherein p is selected from 0, 1 and 2;

V and Q are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, C₁-C₆ heteroalkyl, C₃-C₆ cycloalkyl C₁-C₆ alkyl, C₃-C₆ heterocycloalkyl C₁-C₆ alkyl, arylalkyl and —CR¹R²-W, wherein R¹ and R² are independently selected from H and C₁-C₆ alkyl; or R¹ and R² can form an C₃-C₆ cycloalkyl with the carbon they are attached to;
W is selected from hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl C₁-C₆ alkyl, aryl and heteroaryl; with at least one of V and Q being other than hydrogen; and pharmaceutically acceptable salts thereof.

20 6. A compound of claim 5 wherein n is 1 or 2.

7. A compound of claim 1 having the following Formula III:



25

 wherein R is C(=O)Z where Z is selected from hydrogen, hydroxy, optionally substituted alkoxy and optionally substituted alkyl; or R is amino or optionally substituted alkylamine;

U is $(CH_2)_p$ wherein p is selected from 0, 1 and 2;


V and Q are each independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, C₁-C₆ heteroalkyl, C₃-C₆ cycloalkyl C₁-C₆ alkyl, C₃-C₆ heterocycloalkyl C₁-C₆ alkyl, arylalkyl and –

5 CR¹R²-W, wherein R¹ and R² are independently selected from H and C₁-C₆ alkyl; or R¹ and R² can form an C₃-C₆ cycloalkyl with the carbon they are attached to;

W is selected from hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ heterocycloalkyl C₁-C₆ alkyl, aryl and heteroaryl; with at least one of V and Q being other than hydrogen; and pharmaceutically acceptable salts thereof.

10

8. A compound of claim 1 having the following Formula IV:



15 wherein R is C(=O)Z where Z is selected from hydrogen, hydroxy, optionally substituted alkoxy and optionally substituted alkyl; or R is amino or optionally substituted alkylamine;

n is an integer selected from 0, 1, 2, 3, 4 and 5;


U is $(CH_2)_p$ wherein p is selected from 0, 1 and 2;

20 Q is optionally substituted from alkyl, preferably having 1 to about 12 carbon atoms, optionally substituted alkenyl preferably having 2 to about 12 carbon atoms, optionally substituted alkynyl preferably having from 2 to about 12 carbon atoms, C₁-C₆ heteroalkyl, C₃-C₆ cycloalkyl C₁-C₆ alkyl, C₃-C₆ heterocycloalkyl C₁-C₆ alkyl, aryl C₁-C₆ alkyl and –CR¹R²-W, wherein R¹ and R² are independently selected from H and C₁-C₆ alkyl; or R¹ and R² can form a C₃-C₆ cycloalkyl with the carbon they are attached to;

25 W is selected from hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ heterocycloalkyl C₁-C₆ alkyl, aryl, heteroaryl and aryl C₁-C₆ alkyl; and pharmaceutically acceptable salts thereof.

30 9. A compound of any one of claims 1 through 8 wherein p is zero.

10. A compound of claim 1 having the following Formula V:



V

wherein R is C(=O)Z where Z is selected from hydrogen, hydroxy, optionally substituted alkoxy and optionally substituted alkyl; or R is amino or optionally substituted alkylamine;

10 n is an integer selected from 0, 1, 2, 3, 4 and 5;

Q is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted arylalkyl, C₁-C₆ heteroalkyl, C₃-C₆ cycloalkyl C₁-C₆ alkyl, C₃-C₆ heterocycloalkyl C₁-C₆ alkyl, aryl C₁-C₆ alkyl and -CR¹R²-W, wherein R¹ and R² are independently selected from H and C₁-C₆ alkyl; or R¹ and R² can form an C₃-C₆ cycloalkyl with the carbon they are attached to;

W is selected from hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl C₁-C₆ alkyl, aryl, heteroaryl and aryl C₁-C₆ alkyl; and pharmaceutically acceptable salts thereof.

20 11. A compound of claim 10 wherein n is 1 and R is a *para*-substituent.

12. A compound of claim 10 wherein R is -C(O)OH.

13. A compound of claim 10 wherein Q is straight or branched C₁-C₁₂ alkyl or
25 optionally substituted arylalkyl.

14. A compound of claim 10 wherein R is -C(O)OH being in a "para" position
whereby n is 1; Q is CR¹R²-W, wherein R¹ and R² are independently selected from H
and C₁-C₆ alkyl; or R¹ and R² can form an C₃-C₆ cycloalkyl with the carbon they are
30 attached to; W is selected from hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₃-C₆ cycloalkyl,
C₃-C₆ cycloalkyl C₁-C₆ alkyl, aryl, heteroaryl and aryl C₁-C₆ alkyl; and pharmaceutically
acceptable salts thereof.

15. A compound of claim 10 wherein R is -C(O)OH is in a "para" position; n is 1; Q is CR¹R²-W, wherein R¹ and R² are independently selected from H and C₁-C₆ alkyl; or R¹ and R² can form a C₃-C₆ cycloalkyl with the carbon they are attached to; W is selected from hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl C₁-C₆ alkyl, and aryl; and 5 pharmaceutically acceptable salts thereof.
16. A compound of claim 1 that is selected from the group consisting of:
4-(2-{(2R)-2-[(1E,4S)-4-hydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
4-(2-{(2R)-2-[(1E,4R)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxopyrrolidin-1-10 yl}ethyl)benzoic acid;
4-[2-((2R)-2-{(1E,4R)-4-[1-(cyclopropylmethyl)cyclobutyl]-4-hydroxybut-1-enyl}-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
4-(2-{(2R)-2-[(1E,4R)-4-(1-ethylcyclobutyl)-4-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
15 4-(2-{(2R)-2-[(1E,3S)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
4-(2-{(2S)-2-[(1E,4S)-4-hydroxy-4-ethyloct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
-(2-{(2S)-2-[(1E,4S)-4-hydroxy-4-ethyloct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic 20 acid;
4-(2-{(2R)-2-[(1E,3S)-3-hydroxyoct-1-en-7-ynyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
4-(2-{(2R)-2-[(1E,3S)-3-hydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzamide;
4-(2-{(2R)-2-[(1E,3R)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxopyrrolidin-1-25 yl}ethyl)benzoic acid;
4-(2-{(2R)-2-[(1E,3R)-4-(allyloxy)-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
4-(2-{(2R)-2-[(1E,3R,7S)-3,7-dihydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
30 4-(2-{(2R)-2-[(1E,3S,7S)-3,7-dihydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
4-(2-{(2R)-2-[(1E,3R,7R)-3,7-dihydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
4-(2-{(2R)-2-[(1E)-3-hydroxy-5-morpholin-4-ylpent-1-enyl]-5-oxopyrrolidin-1-35 yl}ethyl)benzoic acid;
4-(2-{(2R)-2-[(1E,3S)-3-hydroxyhepta-1,6-dienyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;

- 4-(2-((2R)-2-[(1E,3S)-4-cyclopropyl-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3R)-4-cyclopentyl-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 5 4-(2-((2R)-2-[(1E,3S)-4-cyclopentyl-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3R)-4-cyclopropyl-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3S)-3-hydroxy-6-methylhept-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 10 4-(2-((2R)-2-[(1E,3S)-3-hydroxy-5-methylhex-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3S)-3-hydroxy-5,5-dimethylhex-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 15 4-(2-((2R)-2-[(1E,3S)-6-cyclopropyl-3-hydroxyhex-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3R)-3-hydroxy-5-methoxypent-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3S)-3-hydroxy-5-methoxypent-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 20 4-(2-((5R)-2-oxo-5-[(1E,3S)-6,6,6-trifluoro-3-hydroxyhex-1-enyl]pyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3S)-4-cyclohexyl-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 25 4-(2-((2R)-2-[(1E,3S)-3-hydroxypent-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3S)-3-hydroxyhex-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3S)-3-hydroxy-6-methoxyhex-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 30 4-(2-((2R)-2-[(1E,3S,7R)-3,7-dihydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3R)-4-(4-chlorophenyl)-3-hydroxy-4-methylpent-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-[2-((2R)-2-[(1E,3S)-3-[1-(cyclopropylmethyl)cyclobutyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 35 4-[2-((2R)-2-[(1E,3R)-3-[1-(cyclopropylmethyl)cyclobutyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 4-(2-((2S)-2-[(3S)-3-(1-butylcyclobutyl)-3-hydroxypropyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

- 4-(2-((2S)-2-[(3R)-3-(1-butylcyclobutyl)-3-hydroxypropyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3R)-3-hydroxy-3-(1-phenylcyclopentyl)prop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 5 4-(2-((2R)-2-[(1E,3S)-3-hydroxy-3-(1-phenylcyclopentyl)prop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-[2-((2R)-2-[(1E,3R)-3-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 4-[2-((2R)-2-[(1E,3S)-3-[1-(4-chlorophenyl)cyclobutyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 10 4-[2-((2R)-2-[(1E,3S)-3-[1-(4-chlorophenyl)cyclobutyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 4-[2-((2R)-2-[(1E,3R)-3-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 4-[2-((2R)-2-[(1E,3S)-3-[1-(4-methylphenyl)cyclopentyl]prop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 15 4-[2-((2R)-2-[(1E,3R)-3-hydroxy-3-[1-(4-methylphenyl)cyclopentyl]prop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 4-[2-((2R)-2-[(1E,3R)-3-hydroxy-3-[1-(4-methylphenyl)cyclopentyl]prop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 4-(2-((2R)-2-[(1E,3S)-4-(4-chlorophenyl)-3-hydroxy-4-methylpent-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 20 4-[2-((2R)-2-[(1E,3S)-3-[1-(4-fluorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 4-[2-((2R)-2-[(1E,3R)-3-[1-(4-fluorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 25 4-[2-((2R)-2-[(1E,3R)-3-[1-(2-fluorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 4-[2-((2R)-2-[(1E,3S)-3-[1-(2-fluorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 4-[2-((2R)-2-[(1E,3S)-3-[1-(4-chlorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 30 4-[2-((2R)-2-[(1E,3R)-3-[1-(4-chlorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 4-[2-((2R)-2-[(1E,3R)-3-[1-(4-chlorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 4-(2-((2R)-2-[(1E,3S)-3-hydroxy-4-(3-methylphenyl)but-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 35 4-(2-((2R)-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3S)-3-hydroxyhept-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

- 4-(2-{(2R)-2-[(1E,3S)-4-(3-chlorophenyl)-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
- 4-(2-{(2R)-2-[(1E,3S)-3-hydroxy-4-phenylbut-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
- 5 4-(2-{(2S)-2-[(3R)-3-hydroxy-4-methyl-4-phenylpentyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
- 4-(2-{(2R)-2-[(1E,3S)-3-hydroxy-4-methyl-4-phenylpent-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
- 10 4-(2-{(2R)-2-[(1E,3R)-3-hydroxy-4-methyl-4-phenylpent-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
- 4-(2-{(2S)-2-[(3S)-3-hydroxynonyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
- 4-[2-((2R)-2-{(1E,3S)-3-[1-(3-fluorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl}-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 15 4-[2-((2R)-2-{(1E,3R)-3-[1-(3-fluorophenyl)cyclopentyl]-3-hydroxyprop-1-enyl}-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 4-(2-{(2R)-2-[(1E,3S)-3-hydroxynon-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
- 4-[2-((2R)-2-{(1E,3S)-3-hydroxy-3-[1-(2-phenylethyl)cyclobutyl]prop-1-enyl}-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 20 4-[2-((2R)-2-{(1E,3R)-3-hydroxy-3-[1-(2-phenylethyl)cyclobutyl]prop-1-enyl}-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 4-(2-{(2R)-2-[(1E,3S)-3-hydroxy-3-(1-propylcyclobutyl)prop-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid
- 4-(2-{(2R)-2-[(1E,3R)-3-hydroxy-3-(1-propylcyclobutyl)prop-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid
- 25 4-(2-{(2R)-2-[(1E,3R)-3-(1-benzylcyclobutyl)-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
- 4-(2-{(2R)-2-[(1E)-3-hydroxy-3-methyloct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
- 4-(2-{(2R)-2-[(1E)-4-hydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
- 30 4-(2-{(2R)-2-[(1E,3S)-3-(1-butylcyclobutyl)-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
- 4-(2-{(2R)-2-[(1E,3R)-3-(1-butylcyclobutyl)-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
- 4-(2-{(2R)-2-[(1E,3S)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;
- 35 4-(2-{(2R)-2-[(1E,3R)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3S)-3-hydroxy-3-(1-phenylcyclopropyl)prop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3R)-3-hydroxy-3-(1-phenylcyclopropyl)prop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

5 4-(2-((2R)-2-[(1E,3S)-3-hydroxy-7-methyloct-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;

4-(2-((2R)-2-[(1E,3S)-5-cyclopentyl-3-hydroxypent-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid; and pharmaceutically acceptable salts thereof.

10 17. A compound according to claims 1 to 16 for use as a medicament.

18. A method for treating a disease or disorder associated with prostaglandin, comprising administering to a mammal suffering from or susceptible to such a disease or disorder an effective amount of a compound of any one of claims 1 through 16.

15

19. A method of claim 18 wherein the mammal is suffering from or susceptible to asthma.

20. A method of claim 18 wherein the mammal is suffering from or susceptible to hypertension.

21. A method of claim 18 wherein the mammal is suffering from or susceptible to undesired blood clotting.

25 22. A method of claim 18 wherein the mammal is suffering from or susceptible to infertility or a fertility disorder.

23. A method of claim 18 wherein the mammal is suffering from or susceptible to an eosinophil disorder.

30

24. A method of claim 18 wherein the mammal is suffering from sexual dysfunction.

25. A method of claim 18 wherein the mammal is suffering from or susceptible to glaucoma or other disorder involving elevated intraocular pressure.

35

26. A method of claim 18 wherein the mammal is suffering from or susceptible to renal dysfunction.

27. A method of claim 18 wherein the mammal is suffering from or susceptible to an immune deficiency disease or disorder.
- 5 28. A method of claim 18 wherein the mammal is suffering from or susceptible to AIDS.
29. A method of claim 18 wherein the mammal is suffering from or susceptible to undesired bone loss.
- 10 30. A method of claim 18 wherein the mammal is suffering from or susceptible to preterm labor.
- 15 31. A method of claim 18 wherein the mammal is suffering from or susceptible to dysmenorrhea.
32. A method of claim 18 wherein the mammal is a female in late stage pregnancy and in need of control of cervical ripening.
- 20 33. A method of claim 18 wherein the mammal is suffering from or susceptible to preeclampsia or eclampsia.
34. A method of claim 18 wherein the mammal is suffering from or susceptible to ichthyosis.
- 25 35. A method of claim 18 wherein the mammal is suffering from or susceptible to dry eye.
36. A method of claim 18 wherein the mammal is suffering from or susceptible to a 30 sleep disorder.
37. A method of claim 18 wherein the mammal is suffering from or susceptible to gastric ulcers.
- 35 38. A method of claim 18 wherein the mammal is suffering or susceptible to undesired muscle contraction.

39. A method of claim 18 wherein the mammal is suffering or susceptible to inflammatory disorders.

40. A method of claim 18 wherein the mammal is suffering from or susceptible to
5 erectile dysfunction.

41. A method of any one of claims 18 through 40 wherein the mammal is a human.

42. A method of any one of claims 18 through claim 39 wherein the mammal is a
10 female.

43. A method of claim 42 wherein the female is suffering from or susceptible to
infertility.

15 44. A method of claim 42 wherein the female is suffering from an ovulatory
disorder.

45. A method of any one of claims 18 through 41 wherein the mammal is a male.

20 46. A method for treating a mammal suffering from or susceptible to preterm labor,
dysmenorrhea, asthma, hypertension, a fertility disorder, undesired blood clotting,
preelampsia, eclampsia, an eosinophil disorder, undesired bone loss, sexual dysfunction,
renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated
intraocular pressure, a sleep disorder, or a gastric ulcer, inflammatory disorder,
25 comprising administering to the mammal an effective amount of a compound of any one
of claims 1 through 16.

47. Use of a compound of any one of claims 1 through 16 for preparation of a
medicament to treat a disease or disorder associated with prostaglandin.

30 48. Use of a compound of any one of claims 1 through 16 for preparation of a
medicament to treat preterm labor, dysmenorrhea, asthma, hypertension, a fertility
disorder, undesired blood clotting, preelampsia, eclampsia, an eosinophil disorder,
undesired bone loss, sexual dysfunction, renal dysfunction, an immune deficiency
35 disorder, dry eye, ichthyosis, elevated intraocular pressure, a sleep disorder, a gastric
ulcer or an inflammatory disorder.

49. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of any one of claims 1 through 16.

50. A pharmaceutical composition of claim 48 wherein the compound is packaged together with instructions for use of the compound to treat preterm labor, dysmenorrhea, asthma, hypertension, infertility or a fertility disorder, sexual dysfunction, undesired blood clotting, a destructive bone disease or disorder, preeclampsia or eclampsia, an eosinophil disorder, renal dysfunction an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, sleep disorder, or gastric ulcer.

10

51. A method of treating a fertility condition in a female, comprising the administration to said female a prostaglandin EP4 receptor agonist, a pro-drug thereof or a pharmaceutical acceptable salt of said compound, pro-drug or a diastereoisomeric mixture of said compound, salt or pro-drug.

15


52. A method of claim 51 wherein the condition is infertility.

53. A method of claim 51 wherein the condition is an ovulatory disorder.

20 54. A method of any claims 51 to 53 wherein the female is undergoing an ovulation induction or ART treatments.

55. A method of any claims from 51 to 54 wherein the prostaglandin EP4 receptor agonist is selected among compounds of formula VI:

25



wherein A is H or OH, preferably H;

B is selected from C₁-C₆ alkyl, aryl C₁-C₆ alkyl, aryl C₁-C₆ heteroalkyl, heteroaryl C₁-C₆ alkoxy, aryl, heteroaryl, C₃-C₆ cycloalkyl and C₃-C₆ heterocycloalkyl, provided that when B is aryl, heteroaryl, C₃-C₆ cycloalkyl and C₃-C₆ heterocycloalkyl, the undefined bond linking B is a single bond;

The dotted line indicates an optional double bond;

R is C(=O)Z wherein Z is selected from hydrogen, hydroxy, alkoxy, alkyl and aryl; or Z is selected from amino or alkylamine such as -NR¹R² wherein R¹ and R² are independently selected from hydrogen and alkyl, -NHSO₂R³ and -NHC(O)R³ wherein

5 R³ is selected among C₁-C₆ alkyl and aryl; or R is heteroaryl;

U is (CH₂)_p wherein p is an integer selected from 0, 1 and 2;

Q is -CR⁴R⁵-W, wherein R⁴ and R⁵ are independently selected from H, halogen and C₁-C₆ alkyl; or R⁴ and R⁵ can form a C₃-C₆ cycloalkyl with the carbon they are attached to;

10 W is selected from hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ heterocycloalkyl, C₃-C₆ cycloalkyl C₁-C₆ alkyl, C₃-C₆ heterocycloalkyl C₁-C₆ alkyl, aryl, heteroaryl, aryl C₁-C₆ alkyl and heteroaryl C₁-C₆ alkyl; and pharmaceutically acceptable salts thereof.

15 56. A method of claim 55 wherein the prostaglandin EP4 receptor agonist is selected among compounds of formula VI, wherein A is H; B is C₁-C₆ alkyl whereby B is linked by a single bond; R is C(=O)Z wherein Z is selected from hydrogen, hydroxy, alkoxy such as -O-alkyl and alkyl; or Z is selected from amino or alkylamine such as -NR¹R² where R¹ and R² are independently hydrogen or alkyl, -NHSO₂R³ and -NHC(O)R³ 20 wherein R³ is selected among C₁-C₆ alkyl and aryl; U is (CH₂)_p wherein p is 0; Q is -CR⁴R⁵-W, wherein R⁴ and R⁵ are independently selected from H, halogen and C₁-C₆ alkyl; W is selected from C₃-C₆ cycloalkyl, C₃-C₆ heterocycloalkyl, optionally substituted aryl and heteroaryl; and pharmaceutically acceptable salts thereof.

25 57. A method of claim 55 wherein the prostaglandin EP4 receptor agonist is selected among compounds of formula VI, wherein A is H; B is C₁-C₆ alkyl; R is C(=O)Z wherein Z is selected from hydrogen, hydroxy, alkoxy; or R is heteroaryl; U is (CH₂)_p wherein p is 0; Q is -CH₂-W, wherein W is selected from C₃-C₆ cycloalkyl, C₃-C₆ heterocycloalkyl, aryl and heteroaryl; and pharmaceutically acceptable salts thereof.

30

58. A method of claim 55 wherein the prostaglandin EP4 receptor agonist is selected among compounds of formula VI, wherein A is H; B is selected from aryl C₁-C₆ alkoxy, -CH₂-aryl and -CH₂-heteroaryl whereby B is linked by a single bond; R is C(=O)Z wherein Z is selected hydrogen, hydroxy and alkoxy; or R is heteroaryl; U is (CH₂)_p 35 wherein p is 0; Q is -CH₂-W, wherein W is selected from C₃-C₆ cycloalkyl, C₃-C₆ heterocycloalkyl, aryl and heteroaryl; and pharmaceutically acceptable salts thereof.

59. A method of claim 55 wherein the prostaglandin EP4 receptor agonist is selected among compounds of formula VI wherein A is H; B is substituted aryl whereby B is linked by a single bond; R is C(=O)Z wherein Z is hydroxy; U is $(CH_2)_p$, wherein p is 0; Q is $-CR^4R^5-W$, wherein R^4 and R^5 are independently selected from H and C₁-C₆ alkyl; 5 or R^4 and R^5 can form a C₃-C₆ cycloalkyl with the carbon they are attached to; W is selected from C₁-C₆ alkyl, C₃-C₆ cycloalkyl C₁-C₆ alkyl, C₃-C₆ cycloalkyl, aryl and substituted phenyl; and pharmaceutically acceptable salts thereof.

60. A method of claim 55 wherein the prostaglandin EP4 receptor agonist is selected 10 from the group consisting of:

- 4-(2-((2R)-2-[(1E,3S)-3-hydroxy-4-phenylbut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3S)-4-(3-chlorophenyl)-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 15 4-(2-((2R)-2-[(1E,3R)-3-hydroxy-3-(1-phenylcyclopropyl)prop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3S)-6-cyclopropyl-3-hydroxyhex-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3S)-3-hydroxyhepta-1,6-dienyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic 20 acid;
- 4-(2-((2R)-2-[(1E,3S)-3-(1-butylcyclobutyl)-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3S)-3-hydroxy-6-methylhept-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 25 4-[2-((2R)-2-[(1E,3R)-3-[1-(cyclopropylmethyl)cyclobutyl]-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl]benzoic acid;
- 4-(2-((2R)-2-[(1E,3S)-3-hydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3R)-3-(1-butylcyclobutyl)-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 30 4-(2-((2R)-2-[(1E,3R)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2R)-2-[(1E,3S)-3-hydroxynon-1-enyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 4-(2-((2S)-2-[(3R)-3-hydroxy-4-(3-methylphenyl)butyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid;
- 35 4-(2-((2S)-2-[(3R)-3-hydroxy-5-phenylpentyl]-5-oxopyrrolidin-1-yl)ethyl)benzoic acid; and pharmaceutically acceptable salts thereof.